Q3 FY26 quarterly results (October-December 2025)

4,316 companies have declared Q3 FY26 results so far, the latest on 15 Sep 2026.

Across the 3,727 non-financial companies with a year-ago quarter to compare, sales grew +15.1% and net profit +14.8% year on year, and the combined operating margin narrowed 25 bps to 14.1%.

For the 146 banks and lenders, net interest income grew +8.0% and net profit +10.5%.

56% of companies grew net profit; 416 turned a loss into a profit; 37% beat their own profit trend and 48% fell short of it.

Updated 17 Oct 2026, 07:36 IST 4316 declared
The next results season has started: 141 companies have filed results for the quarter ended 30 Sep 2026. See them →

Q3 FY26 scoreboard

Sales growth
+15.1%
YoY, 3727 companies combined; median +8.3%
Net profit growth
+14.8%
YoY combined; median +8.9%
Operating margin
14.1%
-25 bps YoY
Grew profit
56%
416 turnarounds, 346 into loss
Vs own profit trend
37% / 48%
above / below, 15% in line
Banks: NII growth
+8.0%
146 lenders; profit +10.5%
Price since results
-9.5%
median; 0% of 1 stocks up
Other-income heavy
1051
25%+ of pre-tax profit from other income & one-offs

Latest Q3 FY26 results 4316

Page 109 of 144

Indo Euro Indchem Ltd

524458 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -98% below its own trend
  • Operating margin contracted 1140 bps YoY
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -70.2%-55.2% 1.32.84.2
Operating profit to lossloss widened -0.1-0.00.2
OPM % -1140 bps-643 bps -7.1%-0.7%4.3%
Other income -15.4%-26.7% 0.10.10.1
Net profit -95.2%-88.9% 0.00.10.2
PAT margin % -417 bps-241 bps 0.8%3.2%5.0%
EPS (₹) -95.7%-90.0% 0.010.100.23

Quality of profit

Pre-tax profit ₹0.0 Cr: core business −₹0.1 Cr, other income ₹0.1 Cr.

Core profit YoY: to loss · reported profit -95.2%

Cash & debt

FY25 cash from operations ₹0.4 Cr: 106% of FY25 net profit of ₹0.4 Cr.

Borrowings nil at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹7.6₹1.3 -83.5% below
Net profit₹0.4₹0.0 -97.6% below

Riddhi Siddhi Gluco Biols Ltd

524480 · Q3 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Operating margin contracted 1273 bps YoY
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -9.1%+25.0% 40.032.044.0
Operating profit loss widenedto loss -6.02.0-1.0
OPM % -1273 bps-2125 bps -15.0%6.2%-2.3%
Other income from loss-38.1% 13.021.0-53.0
Net profit? loss narrowedto loss -1.014.0-54.0
PAT margin % —-4625 bps -2.5%43.8%—
EPS (₹) loss narrowedto loss -2.2318.99-50.56

Quality of profit

Pre-tax profit ₹1.0 Cr: core business −₹12.0 Cr, other income ₹13.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations −₹28.0 Cr.

Borrowings ₹101 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹26.4₹40.0 +51.3% above

SVC INDUSTRIES Ltd

524488 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating margin expanded 3567 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +5.6%-90.6% 0.22.00.2
Operating profit loss narrowedloss widened -0.1-0.1-0.1
OPM % +3567 bps-3963 bps -42.1%-2.5%-77.8%
Other income —— 0.00.00.0
Net profit loss narrowedloss widened -0.6-0.5-0.7
EPS (₹) loss narrowed— -0.03-0.03-0.04

Quality of profit

Pre-tax profit −₹0.6 Cr: core business −₹0.6 Cr, other income ₹0.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹1.5 Cr.

Borrowings ₹175 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹0.4₹0.2 -47.2% below

Raaj Medisafe India Ltd

524502 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +12% above its own trend
  • Operating margin expanded 260 bps YoY
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +41.9%+12.6% 20.718.414.6
Operating profit +66.2%+34.2% 3.72.82.2
OPM % +260 bps+287 bps 17.8%14.9%15.2%
Other income from loss-82.6% 0.00.2-0.0
Net profit +83.5%+9.2% 1.91.71.0
PAT margin % +207 bps-28 bps 9.1%9.4%7.1%
EPS (₹) +84.6%+9.1% 1.441.320.78

Quality of profit

Core 98%Other income & one-offs 2%

Pre-tax profit ₹1.9 Cr: core business ₹1.8 Cr, other income ₹0.0 Cr.

Core profit YoY: +39.2% · reported profit +83.5%

Cash & debt

FY25 cash from operations −₹0.1 Cr: -1% of FY25 net profit of ₹6.5 Cr.

Borrowings ₹34.6 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹22.9₹20.7 -9.5% below
Net profit₹1.7₹1.9 +11.6% above

Coral Laboratories Ltd

524506 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -35% below its own trend
  • Operating margin contracted 1872 bps YoY
  • 67% of pre-tax profit came from other income and one-off items
  • Profit grew faster than the core business (core profit -79%)
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -6.2%+13.3% 21.619.023.0
Operating profit -70.1%-61.7% 1.94.96.3
OPM % -1872 bps-1719 bps 8.8%26.0%27.5%
Other income -1.2%-17.8% 2.53.02.5
Net profit -54.7%-52.2% 2.85.86.1
PAT margin % -1381 bps-1769 bps 12.9%30.6%26.7%
EPS (₹) -54.7%-52.2% 7.7816.2917.19

Quality of profit

Core 32%Other income & one-offs 68%

Pre-tax profit ₹3.7 Cr: core business ₹1.2 Cr, other income ₹2.5 Cr.

Core profit YoY: -79.3% · reported profit -54.7%

Cash & debt

FY25 cash from operations −₹1.0 Cr: -4% of FY25 net profit of ₹24.1 Cr.

Borrowings ₹4.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹18.0₹21.6 +19.6% above
Net profit₹4.3₹2.8 -35.4% below

Tulasee Bio Ethanol Ltd

524514 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales —— 0.00.00.0
Operating profit loss widenedloss widened -0.0-0.0-0.0
Other income —— 0.00.00.0
Net profit loss widenedloss widened -0.0-0.0-0.0
EPS (₹) loss widenedloss widened -0.07-0.05-0.03

Quality of profit

Pre-tax profit −₹0.0 Cr: core business −₹0.0 Cr, other income ₹0.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations ₹0.0 Cr.

Borrowings ₹7.4 Cr at Mar 2025.

Bacil Pharma Ltd

524516 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Turnaround: profit against a loss a year ago
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales —— 0.00.00.0
Operating profit loss narrowedloss narrowed -0.0-0.0-0.1
Other income —+20.0% 0.10.10.0
Net profit from loss+300.0% 0.00.0-0.1
EPS (₹) from loss+200.0% 0.030.01-0.10

Quality of profit

Pre-tax profit ₹0.0 Cr: core business −₹0.0 Cr, other income ₹0.1 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations ₹0.4 Cr: 98% of FY25 net profit of ₹0.4 Cr.

Borrowings ₹0.2 Cr at Mar 2025.

KMC Speciality Hospitals (India) Ltd

524520 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +57% above its own trend
  • Operating margin expanded 426 bps YoY
  • Core business grew faster than reported profit (core profit +100%)
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +34.4%+9.3% 82.075.061.0
Operating profit +56.2%+19.0% 25.021.016.0
OPM % +426 bps+249 bps 30.5%28.0%26.2%
Other income +0.0%+0.0% 1.01.01.0
Net profit +75.0%+27.3% 14.011.08.0
PAT margin % +396 bps+241 bps 17.1%14.7%13.1%
EPS (₹) +82.6%+27.3% 0.840.660.46

Quality of profit

Core 100%Other income & one-offs 0%

Pre-tax profit ₹18.0 Cr: core business ₹18.0 Cr, other income ₹1.0 Cr, exceptional & other items −₹1.0 Cr.

Core profit YoY: +100.0% · reported profit +75.0%

Cash & debt

FY25 cash from operations ₹58.0 Cr: 252% of FY25 net profit of ₹23.0 Cr.

Borrowings ₹89.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹79.4₹82.0 +3.3% in line
Net profit₹8.9₹14.0 +57.5% above

Laffans Petrochemicals Ltd

524522 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Turnaround: profit against a loss a year ago
  • Operating margin contracted 400 bps YoY
  • All of pre-tax profit came from other income or one-off items
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -11.9%-46.1% 1.01.81.1
Operating profit loss narrowedloss narrowed -0.5-0.6-0.5
OPM % -400 bps-1413 bps -49.0%-34.8%-45.0%
Other income from lossfrom loss 2.3-3.8-1.4
Net profit from lossfrom loss 1.6-4.3-2.0
EPS (₹) from lossfrom loss 1.95-5.39-2.55

Quality of profit

Pre-tax profit ₹1.7 Cr: core business −₹0.6 Cr, other income ₹2.3 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹6.5 Cr: -325% of FY25 net profit of ₹2.0 Cr.

Borrowings ₹0.4 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹0.5₹1.0 +76.1% above

Bhaskar Agrochemicals Ltd

524534 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +19% above its own trend
  • FY25 operating cash flow was only 26% of profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +22.2%-26.6% 29.740.524.3
Operating profit +25.7%-19.6% 4.35.33.4
OPM % +40 bps+125 bps 14.3%13.1%14.0%
Other income to lossto loss -0.40.00.0
Net profit +32.2%-28.7% 2.33.31.8
PAT margin % +60 bps-23 bps 7.9%8.1%7.3%
EPS (₹) +32.1%-28.7% 4.496.303.40

Quality of profit

Pre-tax profit ₹3.0 Cr: core business ₹3.4 Cr, other income −₹0.4 Cr.

Core profit YoY: +35.2% · reported profit +32.2%

Cash & debt

FY25 cash from operations ₹1.0 Cr: 26% of FY25 net profit of ₹3.9 Cr.

Borrowings ₹20.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹39.4₹29.7 -24.7% below
Net profit₹2.0₹2.3 +18.5% above

Sharma East India Hospitals & Medical Research Ltd

524548 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -51% below its own trend
  • Operating margin contracted 264 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +17.9%+2.5% 9.69.48.2
Operating profit -11.6%-19.1% 0.80.90.9
OPM % -264 bps-211 bps 7.9%10.0%10.6%
Other income +25.0%+0.0% 0.10.10.0
Net profit -37.9%-43.8% 0.20.30.3
PAT margin % -169 bps-154 bps 1.9%3.4%3.6%

Quality of profit

Core 80%Other income & one-offs 20%

Pre-tax profit ₹0.2 Cr: core business ₹0.2 Cr, other income ₹0.1 Cr.

Core profit YoY: -42.9% · reported profit -37.9%

Cash & debt

FY25 cash from operations ₹6.7 Cr: 535% of FY25 net profit of ₹1.2 Cr.

Borrowings ₹2.3 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹11.4₹9.6 -15.8% below
Net profit₹0.4₹0.2 -51.1% below

Gayatri BioOrganics Ltd

524564 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales —— 0.00.00.0
Operating profit loss widenedloss widened -0.1-0.1-0.1
Other income —— 0.00.00.0
Net profit loss widenedloss widened -0.2-0.2-0.2
EPS (₹) loss widened— -0.03-0.03-0.02

Quality of profit

Pre-tax profit −₹0.2 Cr: core business −₹0.2 Cr, other income ₹0.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations −₹0.6 Cr.

Borrowings ₹36.9 Cr at Mar 2025.

Pharmaids Pharmaceuticals Ltd

524572 · Q3 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Operating margin expanded 1513 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +15.3%-36.9% 5.48.64.7
Operating profit loss narrowedloss narrowed -2.5-5.3-2.9
OPM % +1513 bps+1556 bps -46.2%-61.8%-61.4%
Other income —to loss -0.33.00.0
Net profit? loss narrowedloss widened -2.6-2.6-3.0
PAT margin % +1510 bps-1895 bps -48.8%-29.8%-63.9%
EPS (₹) loss widenedloss narrowed -0.70-0.71-0.55

Quality of profit

Pre-tax profit −₹4.0 Cr: core business −₹3.7 Cr, other income −₹0.3 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹14.0 Cr.

Borrowings ₹39.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹7.2₹5.4 -24.4% below

Vivid Global Industries Ltd

524576 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +17% above its own trend
  • Operating margin contracted 169 bps YoY
  • 65% of pre-tax profit came from other income and one-off items
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +91.8%+5.8% 14.713.97.7
Operating profit +24.3%-22.0% 0.50.60.4
OPM % -169 bps-112 bps 3.1%4.2%4.8%
Other income +30.8%+13.3% 0.20.10.1
Net profit +111.1%+11.8% 0.20.20.1
PAT margin % +12 bps+7 bps 1.3%1.2%1.2%
EPS (₹) +110.0%+10.5% 0.210.190.10

Quality of profit

Core 35%Other income & one-offs 65%

Pre-tax profit ₹0.3 Cr: core business ₹0.1 Cr, other income ₹0.2 Cr.

Core profit YoY: — · reported profit +111.1%

Cash & debt

FY25 cash from operations ₹2.2 Cr: 574% of FY25 net profit of ₹0.4 Cr.

Borrowings ₹2.5 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹8.3₹14.7 +77.2% above
Net profit₹0.2₹0.2 +16.7% above

Priya Ltd

524580 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Turnaround: profit against a loss a year ago
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales —— 0.00.00.0
Operating profit loss narrowed— -0.0-0.0-0.1
Other income —— 8.00.00.0
Net profit from lossfrom loss 7.1-0.9-1.1
EPS (₹) from lossfrom loss 23.75-3.16-3.50

Quality of profit

Pre-tax profit ₹7.1 Cr: core business −₹0.9 Cr, other income ₹8.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹0.2 Cr.

Borrowings ₹26.1 Cr at Mar 2025.

Tirupati Starch & Chemicals Ltd

524582 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -83% below its own trend
  • Operating margin contracted 704 bps YoY
  • 60% of pre-tax profit came from other income and one-off items
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -7.3%+3.0% 91.989.299.2
Operating profit -55.7%+33.2% 5.94.513.4
OPM % -704 bps+146 bps 6.5%5.0%13.5%
Other income from loss+475.7% 2.10.4-0.1
Net profit -66.9%— 2.50.27.4
PAT margin % -481 bps+243 bps 2.7%0.2%7.5%
EPS (₹) -66.8%— 2.570.237.75

Quality of profit

Core 40%Other income & one-offs 60%

Pre-tax profit ₹3.5 Cr: core business ₹1.4 Cr, other income ₹2.1 Cr.

Core profit YoY: -84.3% · reported profit -66.9%

Cash & debt

FY25 cash from operations ₹49.0 Cr: 650% of FY25 net profit of ₹7.5 Cr.

Borrowings ₹136 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹110₹91.9 -16.2% below
Net profit₹14.9₹2.5 -83.4% below

Hemo Organic Ltd

524590 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales —— 0.00.00.0
Operating profit loss narrowedloss widened -0.1-0.0-0.1
Other income —— 0.00.00.0
Net profit loss widenedloss widened -0.2-0.0-0.1
EPS (₹) loss widenedloss widened -0.46-0.09-0.23

Quality of profit

Pre-tax profit −₹0.1 Cr: core business −₹0.1 Cr, other income ₹0.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹0.4 Cr: -171% of FY25 net profit of ₹0.2 Cr.

Borrowings ₹1.5 Cr at Mar 2025.

Jaysynth Orgochem Ltd

524592 · Q3 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit -59% below its own trend
  • Operating margin contracted 525 bps YoY
  • FY25 operating cash flow was only 45% of profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +8.3%-0.6% 65.465.860.4
Operating profit -42.3%-38.7% 3.96.46.8
OPM % -525 bps-372 bps 6.0%9.7%11.2%
Other income -64.9%-66.2% 0.51.61.5
Net profit? -57.3%-52.9% 2.35.05.5
PAT margin % -548 bps-396 bps 3.6%7.5%9.0%
EPS (₹) -57.5%-54.1% 0.170.370.40

Quality of profit

Core 84%Other income & one-offs 16%

Pre-tax profit ₹3.3 Cr: core business ₹2.8 Cr, other income ₹0.5 Cr.

Core profit YoY: -49.9% · reported profit -57.3%

Cash & debt

FY25 cash from operations ₹7.0 Cr: 45% of FY25 net profit of ₹15.6 Cr.

Borrowings ₹46.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹69.9₹65.4 -6.5% below
Net profit₹5.7₹2.3 -58.9% below

Aeonx Digital Technology Ltd

524594 · Q3 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Into loss: a profit a year ago
  • Profit -261% below its own trend
  • Operating margin contracted 932 bps YoY
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +86.9%+49.3% 15.910.68.5
Operating profit to lossloss widened -0.6-0.10.5
OPM % -932 bps-271 bps -4.0%-1.3%5.3%
Other income -73.0%-71.2% 0.31.21.3
Net profit? to lossto loss -0.70.30.8
PAT margin % -1398 bps-751 bps -4.2%3.3%9.8%
EPS (₹) to lossto loss -1.460.761.80

Quality of profit

Pre-tax profit −₹0.8 Cr: core business −₹1.2 Cr, other income ₹0.3 Cr.

Core profit YoY: to loss

Cash & debt

FY25 cash from operations −₹4.6 Cr: -114% of FY25 net profit of ₹4.0 Cr.

Borrowings ₹0.9 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹8.5₹15.9 +88.0% above
Net profit₹0.4−₹0.7 -261.4% below

Bandaram Pharma Packtech Ltd

524602 · Q3 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Turnaround: profit against a loss a year ago
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +48.4%+8.2% 14.813.710.0
Operating profit +51.5%+122.2% 1.00.50.7
OPM % +14 bps+346 bps 6.7%3.3%6.6%
Other income —-100.0% 0.00.00.0
Net profit? from loss+483.3% 0.30.1-0.0
PAT margin % +256 bps+192 bps 2.4%0.4%-0.2%
EPS (₹) from loss+450.0% 0.110.02-0.01

Quality of profit

Core 100%Other income & one-offs 0%

Pre-tax profit ₹0.5 Cr: core business ₹0.5 Cr, other income ₹0.0 Cr.

Core profit YoY: +96.3%

Cash & debt

FY25 cash from operations −₹4.9 Cr: -503% of FY25 net profit of ₹1.0 Cr.

Borrowings ₹17.1 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹10.4₹14.8 +43.3% above

Adline Chem Lab Ltd

524604 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales —— 0.00.00.0
Operating profit loss narrowedloss narrowed -0.0-0.1-0.1
Other income —— 0.00.00.0
Net profit loss narrowedloss narrowed -0.1-0.1-0.1
EPS (₹) loss narrowedloss narrowed -0.10-0.12-0.21

Quality of profit

Pre-tax profit −₹0.1 Cr: core business −₹0.1 Cr, other income ₹0.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹0.2 Cr.

Borrowings ₹1.5 Cr at Mar 2025.

Beryl Drugs Ltd

524606 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Into loss: a profit a year ago
  • Profit -780% below its own trend
  • Operating margin contracted 1612 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -28.7%-25.4% 3.95.25.4
Operating profit to lossto loss -0.20.70.6
OPM % -1612 bps-1934 bps -5.2%14.1%10.9%
Other income —— 0.00.00.0
Net profit to lossto loss -0.20.00.1
PAT margin % -534 bps-461 bps -4.4%0.2%0.9%
EPS (₹) to lossto loss -0.340.020.10

Quality of profit

Pre-tax profit −₹0.6 Cr: core business −₹0.6 Cr, other income ₹0.0 Cr.

Core profit YoY: to loss

Cash & debt

FY25 cash from operations ₹2.6 Cr: 455% of FY25 net profit of ₹0.6 Cr.

Borrowings ₹4.1 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹4.5₹3.9 -15.3% below
Net profit₹0.0−₹0.2 -780.0% below

IEL Ltd

524614 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating margin expanded 1432 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +37.5%— 0.60.00.4
Operating profit +66.7%from loss 0.5-0.10.3
OPM % +1432 bps— 81.8%—67.5%
Other income +50.0%— 0.00.00.0
Net profit +123.8%from loss 0.5-0.10.2
PAT margin % +3295 bps— 85.5%—52.5%
EPS (₹) +100.0%from loss 0.04-0.010.02

Quality of profit

Core 94%Other income & one-offs 6%

Pre-tax profit ₹0.5 Cr: core business ₹0.4 Cr, other income ₹0.0 Cr.

Core profit YoY: +69.2% · reported profit +123.8%

Cash & debt

FY25 cash from operations ₹2.1 Cr: 491% of FY25 net profit of ₹0.4 Cr.

Borrowings ₹0.9 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹0.2₹0.6 +175.0% above

iStreet Network Ltd

524622 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Turnaround: profit against a loss a year ago
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales —+32.2% 24.718.60.0
Operating profit from loss+58.9% 1.40.9-0.0
OPM % —+97 bps 5.8%4.8%—
Other income —— 0.00.00.0
Net profit from loss+33.3% 1.20.9-0.0
PAT margin % —+4 bps 4.9%4.8%—
EPS (₹) from loss-57.1% 0.180.42-0.01

Quality of profit

Core 100%Other income & one-offs 0%

Pre-tax profit ₹1.4 Cr: core business ₹1.4 Cr, other income ₹0.0 Cr.

Core profit YoY: from loss

Cash & debt

FY25 cash from operations −₹0.0 Cr: -8% of FY25 net profit of ₹0.2 Cr.

Borrowings ₹1.8 Cr at Mar 2025.

Gagan Gases Ltd

524624 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -56% below its own trend
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -8.1%+3.6% 1.71.61.9
Operating profit -16.7%+900.0% 0.10.00.1
OPM % -60 bps+524 bps 5.8%0.6%6.5%
Other income —— 0.00.00.0
Net profit -11.1%from loss 0.1-0.00.1
PAT margin % -16 bps+528 bps 4.7%-0.6%4.8%
EPS (₹) -10.0%from loss 0.18-0.020.20

Quality of profit

Core 100%Other income & one-offs 0%

Pre-tax profit ₹0.1 Cr: core business ₹0.1 Cr, other income ₹0.0 Cr.

Core profit YoY: -20.0% · reported profit -11.1%

Cash & debt

FY25 cash from operations ₹0.3 Cr: 96% of FY25 net profit of ₹0.3 Cr.

Borrowings ₹0.4 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹2.6₹1.7 -34.2% below
Net profit₹0.2₹0.1 -55.6% below

Parker Agrochem Exports Ltd

524628 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +31% above its own trend
  • Operating margin expanded 2399 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales -97.3%-3.3% 1.51.553.5
Operating profit from loss-32.7% 0.30.5-0.0
OPM % +2399 bps-1046 bps 24.0%34.4%-0.0%
Other income +0.0%+0.0% 0.00.00.0
Net profit +83.3%-76.6% 0.10.50.1
PAT margin % +742 bps-2359 bps 7.5%31.1%0.1%
EPS (₹) +76.9%-76.5% 0.230.980.13

Quality of profit

Core 97%Other income & one-offs 3%

Pre-tax profit ₹0.3 Cr: core business ₹0.3 Cr, other income ₹0.0 Cr.

Core profit YoY: from loss · reported profit +83.3%

Cash & debt

FY25 cash from operations ₹0.3 Cr.

Borrowings ₹1.1 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹107₹1.5 -98.6% below
Net profit₹0.1₹0.1 +30.8% above

Shukra Pharmaceuticals Ltd

524632 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +273% above its own trend
  • Operating margin expanded 3219 bps YoY
  • Core business grew faster than reported profit (core profit +744%)
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +269.8%+565.5% 39.15.910.6
Operating profit +590.3%from loss 27.1-0.43.9
OPM % +3219 bps+7631 bps 69.3%-7.0%37.1%
Other income -18.8%-52.0% 0.81.71.0
Net profit +544.3%+755.5% 20.42.43.2
PAT margin % +2216 bps+1156 bps 52.0%40.5%29.9%
EPS (₹) +557.1%+820.0% 0.460.050.07

Quality of profit

Core 97%Other income & one-offs 3%

Pre-tax profit ₹26.8 Cr: core business ₹26.0 Cr, other income ₹0.8 Cr.

Core profit YoY: +744.5% · reported profit +544.3%

Cash & debt

FY25 cash from operations ₹8.0 Cr: 84% of FY25 net profit of ₹9.6 Cr.

Borrowings ₹4.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹12.0₹39.1 +224.8% above
Net profit₹5.5₹20.4 +273.2% above

Alufluoride Ltd

524634 · Q3 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit +55% above its own trend
  • Operating margin expanded 118 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +23.1%+6.9% 58.654.847.6
Operating profit +29.5%+0.5% 14.013.910.8
OPM % +118 bps-151 bps 23.9%25.4%22.8%
Other income +784.6%+194.9% 1.10.40.1
Net profit? +55.9%+18.9% 9.47.96.0
PAT margin % +338 bps+163 bps 16.1%14.5%12.7%
EPS (₹) +55.8%+18.9% 12.0610.147.74

Quality of profit

Core 91%Other income & one-offs 9%

Pre-tax profit ₹12.2 Cr: core business ₹11.0 Cr, other income ₹1.1 Cr.

Core profit YoY: +39.0% · reported profit +55.9%

Cash & debt

FY25 cash from operations ₹12.0 Cr: 67% of FY25 net profit of ₹18.0 Cr.

Borrowings ₹30.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹58.2₹58.6 +0.6% in line
Net profit₹6.1₹9.4 +55.1% above

Oxygenta Pharmaceutical Ltd

524636 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating margin expanded 110 bps YoY
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +2.2%+137.3% 33.914.333.2
Operating profit loss narrowedloss narrowed -4.1-4.6-4.4
OPM % +110 bps+1993 bps -12.0%-32.0%-13.1%
Other income -100.0%loss narrowed 0.0-0.10.5
Net profit loss widenedloss narrowed -4.8-4.9-3.9
PAT margin % -243 bps+2021 bps -14.3%-34.5%-11.8%
EPS (₹) loss widenedloss narrowed -1.31-1.33-1.06

Quality of profit

Pre-tax profit −₹6.3 Cr: core business −₹6.3 Cr, other income ₹0.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations ₹3.0 Cr.

Borrowings ₹62.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹66.4₹33.9 -48.9% below

Archit Organosys Ltd

524640 · Q3 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +59% above its own trend
  • Operating margin expanded 191 bps YoY
  • 26% of pre-tax profit came from other income and one-off items
  • Core business grew faster than reported profit (core profit +271%)
₹ CrYoYQoQ Dec 2025Sep 2025Dec 2024
Sales +48.4%+16.9% 38.432.925.9
Operating profit +75.9%+73.3% 4.72.72.7
OPM % +191 bps+397 bps 12.2%8.2%10.3%
Other income -3.2%-38.4% 0.91.50.9
Net profit +140.6%+57.8% 2.41.51.0
PAT margin % +242 bps+164 bps 6.3%4.7%3.9%
EPS (₹) +140.8%+57.3% 1.180.750.49

Quality of profit

Core 74%Other income & one-offs 26%

Pre-tax profit ₹3.5 Cr: core business ₹2.6 Cr, other income ₹0.9 Cr.

Core profit YoY: +271.4% · reported profit +140.6%

Cash & debt

FY25 cash from operations ₹19.0 Cr: 375% of FY25 net profit of ₹5.1 Cr.

Borrowings ₹28.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹30.3₹38.4 +26.8% above
Net profit₹1.5₹2.4 +59.4% above

How to read this page

The numbers. Each card is one company's Q3 FY26 results as filed with NSE or BSE, read from the filing within hours of its release, in ₹ crore. We show the consolidated statement, or the standalone one when the consolidated figures are a copy of it or have no year-ago quarter to compare with. YoY compares with the same quarter a year earlier and QoQ with the quarter before (the previous half-year for companies that report every six months). A swing between profit and loss is described in words: a percentage across it would mislead.

Net profit. On a consolidated statement, net profit is the profit of the whole group for the quarter, before minority interest. A company's own headline, and the AI read of its filing, often quote the profit attributable to its shareholders instead, which is lower when subsidiaries are partly owned: Larsen & Toubro's Q1 FY27 group profit was ₹4,988 Cr, of which ₹4,123 Cr belonged to its shareholders. EPS is worked out on that attributable profit, so EPS and net profit need not grow at the same rate. On a standalone statement the two are the same.

Margins. Operating margin (OPM) is operating profit, before depreciation, interest and other income, as a share of sales; PAT margin is net profit as a share of sales. Their changes are in basis points (100 bps = 1 percentage point).

Quality of profit. Core profit is operating profit minus interest and depreciation: what the business itself earned before tax. The rest of pre-tax profit is other income (interest on cash, dividends, gains on investments) and exceptional or one-off items. We flag a quarter when that share is 25% or more, and when reported profit grew much faster than core profit. For banks we compare pre-provision profit with net profit, since a fall in provisions can lift profit without the business growing.

Against its own trend. We do not have analyst consensus estimates, and we do not make them up. Instead each company is measured against the path it was on: the same quarter last year, grown at the median of its last four year-on-year growth rates (held between −50% and +100%; at least two growth rates needed). Sales 5% or more above that, or net profit 10% or more above, is "above trend"; as far below is "below trend". It answers "was this quarter better or worse than the company's own recent run?", which consensus does not.

Cash and debt. Profit is an accounting figure; cash is harder to dress up. For each company we show its operating cash flow for the last financial year as a share of that year's net profit (flagged under 50%, or when it is negative despite a profit), and its borrowings at the latest balance sheet against the one six months earlier (flagged at a 25% move). Balance sheets come with the September and March results, the year's cash-flow statement with the March results and the half-year's (April to September) with the September results.

Management guidance. When a company files the transcript of its earnings call, we read what its management said to expect: revenue or profit growth, margins, capex and the like, for this financial year or part of it. A figure is kept only when the sentence that states it is found in the transcript, and you can read it under "What management said". Growth and margins are then set beside the actual so far: the year-to-date quarters against the same quarters a year earlier (so the first half is measured against a full-year figure). Within 1 percentage point of the range for growth, or 0.5 for margins, is "on track"; above it "ahead", below it "behind". A new figure for the same period is marked raised or cut against the one before. This is what management said, not a forecast of ours.

Working capital. Inventory, trade receivables and trade payables from the same balance sheets, each also as days of sales (the amount against the twelve months' sales to that date, times 365). Receivables or inventory that grow 25 points or more faster than sales between two balance sheets (and by at least 20%) are flagged: money tied up in customers and stock is profit not yet in cash. These lines are read from filings since the September 2026 results, so comparisons with an earlier balance sheet start with the March 2027 results for most companies.

Price since results. The latest close against the last close before the filing (a filing after 3:30 pm counts from the next session). It is a fact about the market's reaction, not advice.

Market cap groups. Large cap is the 100 largest companies by market value and mid cap the next 150 (SEBI's ranking); below that, small cap is ₹5,000 Cr or more, micro cap ₹500 Cr or more, nano cap below.

⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI